Cyp2e1 - cytochrome P450, family 2, subfamily e, polypeptide 1 Gene

Also Known as Cyp2e

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 25086

Summary

Enables HSP70 protein binding activity and HSP90 protein binding activity. Involved in several processes, including response to ethanol; response to ozone; and triglyceride metabolic process. Located in Golgi membrane; endoplasmic reticulum membrane; and mitochondrial inner membrane. Is intrinsic component of endoplasmic reticulum membrane. Used to study drug-induced hepatitis. Biomarker of several diseases, including alcohol use disorder; fatty liver disease (multiple); liver disease (multiple); middle cerebral artery infarction; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in several diseases, including acoustic neuroma; fatty liver disease; gastrointestinal system Cancer (multiple); liver disease (multiple); and lung disease (multiple). Orthologous to human CYP2E1 (Cytochrome P450 family 2 subfamily E member 1). [provided by Alliance of Genome Resources, Apr 2022]

Cyp2e1 Products (1)

mRNA Protein Name
NM_031543.2 NP_113731.2 cytochrome P450 2E1

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables Hsp70 protein binding IDA
IDA: Inferred from direct assay
19401463 RGD
enables Hsp90 protein binding IDA
IDA: Inferred from direct assay
19401463 RGD
Biological Process GO Annotation Evidence References Source
involved in response to 3-methylcholanthrene IEP
IEP: Inferred from expression pattern
19889059 RGD
involved in response to ethanol IEP
IEP: Inferred from expression pattern
16337197 RGD
involved in response to ozone IEP
IEP: Inferred from expression pattern
9571988 RGD
involved in response to xenobiotic stimulus IEP
IEP: Inferred from expression pattern
21170329 RGD
involved in triglyceride metabolic process IMP
IMP: Inferred from mutant phenotype
20116195 RGD
involved in xenobiotic metabolic process IMP
IMP: Inferred from mutant phenotype
21187827 RGD
Cellular Component GO Annotation Evidence References Source
located in Golgi membrane IDA
IDA: Inferred from direct assay
8809087 RGD
located in endoplasmic reticulum membrane IDA
IDA: Inferred from direct assay
19401463 RGD
located in mitochondrial inner membrane IDA
IDA: Inferred from direct assay
19401463 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

cytochrome P450 2E1

  • 4-nitrophenol 2-hydroxylase

  • CYPIIE1

  • P450-J

  • P450RLM6

  • cytochrome P450 subfamily 2e1 (ethanol-inducible)

  • cytochrome P450, subfamily 2E, polypeptide 1

  • cytochrome P450-J

  • cytochrome P450RLM6

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-N6972 Cepharanthine 99.87% Yes
HY-B0876 Fomepizole Inhibitor 99.78% Yes
HY-B0876A Fomepizole hydrochloride Inhibitor 99.85% Yes

Clinical Phase

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Phase
HY-111375 Azoxymethane 99.45% Phase 4
HY-Y0698 Thioacetamide 98.0% Phase 4
HY-B1351 Bilberry Extract / Phase 4
HY-129105 Clomethiazole 99.35% Phase 3
HY-W075176 Transfluthrin / Phase 3
HY-116228 Cadrofloxacin Inhibitor 98.21% Phase 2

Pre-clinical Phase

Bioactive Molecules (36)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-N0692 Schisandrol B 99.92% Unkown
HY-W013268 (S)-(+)-N-3-Benzylnirvanol Inhibitor 99.76% Unkown
HY-D0848 N,N'-Methylenebisacrylamide Activator 99.98% Unkown
HY-W042193 2-Piperidone 99.89% Unkown
HY-N0592A Demethyleneberberine chloride 98.90% Unkown
HY-Y0110 2-Naphthol 99.91% Unkown
HY-N4110 Friedelin Inhibitor 99.0% Unkown
HY-W072025 CYP2E1-IN-1 99.95% Unkown
HY-78086 m-Tolualdehyde 99.58% Unkown
HY-A0296 Chlormethiazole hydrochloride Inhibitor 99.94% Unkown
HY-W458364 1-(Isothiazol-3-yl)ethan-1-one Inhibitor 99.26% Unkown
HY-N1407 Polygalaxanthone III 99.28% Unkown
HY-B1462S Chlorzoxazone-d3 Modulator 99.88% Unkown
HY-N5132 (-)-Fenchone 98.0% Unkown
HY-N8382 Chalepensin Inhibitor 98.98% Unkown
HY-Y0110S1 2-Naphthol-d7 99.37% Unkown
HY-N0592 Demethyleneberberine ≥98.0% Unkown
HY-N2586 Tenuifoliside C 99.57% Unkown
HY-RS03463 CYP2E1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS16890 Cyp2e1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W066579 4,5,6,7-Tetrahydroindazole / Unkown
HY-W067374 Aripiprazole impurity 38 97.79% Unkown
HY-146177 CYP3A4 enzyme-IN-1 Inhibitor / Unkown
HY-19435 GYKI-47261 / Unkown
HY-19435A GYKI-47261 dihydrochloride / Unkown
HY-E72101 Human CYP2E1, Reductase+b5 / Unkown
HY-N17737 Floramanoside F / Unkown
HY-N20617 (2E,6E,10E)-12-Hydroxyfarnesol / Unkown
HY-W140208 3-Phenylthiophene Inhibitor / Unkown
HY-W710827 N,N'-Methylenebisacrylamide-d6 / Unkown
HY-W724345 Fomepizole-d2 / Unkown
HY-Y0110S 2-Naphthol-d8 / Unkown
HY-119403 4-Phenyl-1,2,3-thiadiazole Inhibitor 99.98% Unkown
HY-78086R m-Tolualdehyde (Standard) / Unkown
HY-N1407R Polygalaxanthone III (Standard) / Unkown
HY-RS23332 Cyp2e1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cyp2e1 NCBI NCBI:1571